Hikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USP
LONDON, June 15, 2023 /PRNewswire/ — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Dobutamine Injection, USP, in a 250mg/20mL vial in the US. With this launch, Hikma’s growing US portfolio of sterile injectable medicines now exceeds 150 products spanning a wide range of therapeutic areas and dosage forms. Table 1 Dobutamine Injection, USP Infusion Rate … Read more